Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen

Abstract

COVID-19 patients are susceptible to hypercoagulability. For the safe return to sports after COVID-19, athletes or individuals wanting to resume physical activity should complete screening for myocardial injury and myocarditis. In addition, patients with COVID-19 are reported at prevalence of 27%-31% for venous thromboembolic events. The probability of deep vein thrombosis and pulmonary embolism prior to intensive exercise after COVID-19 infection should be considered. The prevalence of cardiac injury is reported at 19%, and the prevalence of deep vein thrombosis and pulmonary embolism is higher than that for myocarditis. Thus, the heart is not the only system needing screened. Examination for myocardial injury and myocarditis are mandatory. Also, deep vein thrombosis, and pulmonary thromboembolism must be considered, and when possible, blood troponin values, D-dimer prothrombin time, and activated partial thromboplastin time levels are determined for COVID-19 infection athletes or any individual before returning to sporting practice or intense physical activity or exercise.

Keywords

Athletes / Sports medicine / Myocarditis / Pulmonary embolism / COVID-19 / Screening / Coronavirus / Coagulopathy

References

[[1]] W. Wang, J. Tang, F. Wei.Updated understanding of the outbreak of 2019 novel coronavirus ( 2019-nCoV) in Wuhan, China. J Med Virol, 92 (4) ( 2020), pp. 441-447. https://doi:10.1002/jmv.25689

[[2]] J. Poissy, J. Goutay, M. Caplan, et al.. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation, 142 (2) ( 2020), pp. 184-186. https://doi:10.1161/CIRCULATIONAHA.120.047430

[[3]] D. Wrapp, N. Wang, K.S. Corbett, et al.. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367 (6483) ( 2020), pp. 1260-1263. https://doi:10.1126/science.abb2507

[[4]] G.Y. Oudit, Z. Kassiri, C. Jiang, et al.. SARS-coronavirus modulation of myocardial ACE 2 expression and inflammation in patients with SARS. Eur J Clin Invest, 39 (7) ( 2009), pp. 618-625. https://doi:10.1111/j.1365-2362.2009.02153.x

[[5]] T. Guo, Y. Fan, M. Chen, et al.. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 5 (7) ( 2020), pp. 1-8.

[ published online ahead of print, 2020 Mar 27 ]

[[6]] D. Phelan, J.H. Kim, E.H. Chung.A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection. JAMA Cardiol ( 2020).

[ published online ahead of print, 2020 May 13 ]

[[7]] G.C. Verwoert, S.T. de Vries, N. Bijsterveld, et al.. Return to sports after COVID-19: a position paper from the Dutch sports Cardiology section of The Netherlands society of Cardiology. Neth Heart J, 28 ( 2020), pp. 391-395, DOI: 10.1007/s12471-020-01469-z

[[8]] T. Iba, J.H. Levy, M. Levi, et al.. Coagulopathy of coronavirus disease 2019. Crit Care Med ( 2020).

[ published online ahead of print, 2020 May 27 ]

[[9]] J.M. Connors, J.H. Levy. COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135 (23) ( 2020), pp. 2033-2040, DOI: 10.1182/blood.2020006000

[[10]] W. Miesbach, M. Makris. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost, 26 ( 2020). 1076029620938149. https://doi:10.1177/1076029620938149

To Jonathan A. Drezner and Jackie. For your advice.